Study Finds No Increase in Drug Launch Prices Following IRA Medicare Negotiation Implementation
A recent study by Harvard-affiliated researchers, including Benjamin H. Rome, M.D., M.P.H., indicates that the Inflation Reduction Act (IRA) and its provision for Medicare drug price negotiation have not led to an increase in drug launch prices. Prior to the IRA, drug launch prices, specifically wholesale acquisition cost (WAC) prices, increased by an average of 7.82% per year. Following the implementation of the IRA, the study identified a trend change of -3.71%. While this figure suggests a potential decrease in the rate of price increases, Rome noted that the wide confidence interval around this nominal figure makes its statistical significance questionable. This research challenges earlier concerns from commentators, such as Avalere Health’s Laura Housman, Dr. P.H., M.P.H., MBA, who speculated that drugmakers might increase initial launch prices to offset leaner margins resulting from Medicare's new pricing power. The findings align with previous research from Vanderbilt’s Stacie B. Dusetzina, which al...